© Copyright 2017 Sense Biodetection Limited. Company Registration: 08624309. All rights reserved.
Michael Moore holds a range of non-executive directorships at oncology companies, including Mission Therapeutics, where he is chairman, Trillium and Psioxus. From 2003-2008 he was Chief Executive Officer of Piramed, a UK-based biotech company, which was acquired by Roche in 2008 for $175m. From 1988-2003 he was at Xenova Group plc, becoming a director in 1994. As Chief Scientific Officer he was instrumental in the acquisition of Cantab Pharmaceuticals in 2000.
Previously, Michael held a tenured Cancer Research Campaign position (1980) at the Paterson Institute for Cancer Research, was Honorary Reader in Immunology and Oncology at the University of Manchester Medical School (1986), and Editor-in-chief, British Journal of Cancer (1983).
He received his PhD and DSc from Nottingham University and has more than 150 scientific publications. He is a Fellow of the Royal College of Pathologists and retains the post of Professor Associate in the Department of Cancer Genetics and Pharmacogenomics in the Brunel Institute.
He is a former chairman of Cancer Research UK's drug discovery committee.
Catherine is a serial entrepreneur and director in the fields of biotech and medtech. She has over 25 years’ of biotech industry experience, 12 of which were within the pharma industry leading drug development programmes in a number of disease areas. Since 1999 she has worked extensively to commercialise novel technologies in the life sciences.
She is currently CEO of biopharmaceuticals start-up Exonate and was previously CEO of drug delivery device company Oval Medical Technologies Ltd.
Other directorships include Aitua, Better2Know and Tawhai. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.
John is currently Entrepreneur-in-Residence at Cambridge Enterprise Seed Fund, University of Cambridge. His previous roles include VP R&D at Genzyme Diagnostics and Commercial Director of Diagnostics and Life Sciences at Cambridge Consultants.
He has a wealth of knowledge in the field of diagnostics and devices, with over 30 years’ of experience in the market including advisory roles and board level experience and has worked for companies both in Europe and in the USA. He has experience of managing technology start-ups, state-of-the-art operations, cross-functional teams, IP assets and organisational expansion projects to achieve competitive market advantages and has also spent four years on the MRC's DPFS panel and is a member of the CUHP Innovation Hub panel.
John has a BSc in Biochemistry from Liverpool University, where he also obtained his PhD in a joint project between Biochemistry and Surgery. He has an Executive MBA from Boston University.
Prof John Wain is Professor of Medical Microbiology at the University of East Anglia and is recognised globally as a leading expert in antibiotic resistance. He is the founder and CSO at antimicrobial drug discovery companies Discuva and Bectevo. At UEA he leads a translational research programme in diagnostic microbiology, including antimicrobial resistance and biofilms.
In his earlier career, he spent seven years’ with the South East Asian Oxford University Clinical Research Unit studying genetic diversity in antibiotic resistant bacteria, four years at Imperial College, London and five at the Sanger Institute working on the translation of basic science research into public health-relevant tools.
He is a founding editor for the Journal of Infection in Developing Countries (JIDC) and Chairman of "The Salmonella Network" as well as a member of the WHO advisory group on Integrated Surveillance of Antimicrobial Resistance.
John has authored over 100 peer reviewed scientific papers and patents.